肿瘤3D药敏检测在结直肠癌术后优选化疗方案的临床应用研究

Objective to study the clinical application of tumor 3D drug sensitivity test in the optimal chemotherapy scheme after colorectal cancer surgery

目的研究肿瘤3D药敏检测在结直肠癌术后优选化疗方案的临床应用效果。方法回顾性选取2015年1月—2016年1月抚州市第一人民医院结直肠癌患者100例,依据化疗方案选取方法分为肿瘤3D药敏检测组(药敏组,n=50)、经验化疗组(经验组,n=50),统计分析2组患者的临床疗效及3年、5年生存情况。结果药敏组患者的总缓解率为78.0%,(39/50),显著高于经验组的28.0%(14/50)(P<0.05)。药敏组患者的3年、5年生存率68.0%(34/50)、48.0%(24/50)均显著高于经验组的56.0%(28/50)、28.0%(14/50)(P<0.05)。结论肿瘤3D药敏检测在结直肠癌术后优选化疗方案的临床应用价值显著。

Objective To study the clinical application of 3D drug sensitivity test in the selection of chemotherapy regimen after colorectal cancer surgery.Methods 100 patients with colorectal cancer in our hospital from January 2015 to January 2016 were retrospectively selected and divided into two groups according to the method of chemotherapy scheme selection:tumor 3D drug sensitivity test group(drug sensitivity group,n=50)and empirical chemotherapy group(experience group,n=50).The clinical efficacy,3-year and 5-year survival of the two groups were statistically analyzed.Results the total remission rate was 78.0%(39/50)in the drug sensitive group,which was significantly higher than 28.0%(14/50)in the experience group(P<0.05).The 3-year and 5-year survival rates were 68.0%(34/50)and 48.0%(24/50)in the drug sensitive group,which were significantly higher than 56.0%(28/50)and 28.0%(14/50)in the experience group(P<0.05).Conclusion 3D drug sensitivity test has high clinical application value in the selection of chemotherapy regimen after colorectal cancer surgery.